Search

Your search keyword '"Eisenhauer, Elizabeth A."' showing total 301 results
Start Over Author "Eisenhauer, Elizabeth A." Publication Type Academic Journals
301 results on '"Eisenhauer, Elizabeth A."'

1. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology

Author

Del Paggio, Joseph C, Berry, John S, Hopman, Wilma M, Eisenhauer, Elizabeth A, Prasad, Vinay, Gyawali, Bishal, and Booth, Christopher M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Digestive Diseases, Carcinoma, Non-Small-Cell Lung, Drug Industry, Humans, Lung Neoplasms, Medical Oncology, Progression-Free Survival, Public Health and Health Services, Oncology and carcinogenesis
Abstract

ImportanceThe randomized clinical trial (RCT) in oncology has evolved since its widespread adoption in the 1970s. In recent years, concerns have emerged regarding the use of putative surrogate end points, such as progression-free survival (PFS), and marginal effect sizes.ObjectiveTo describe contemporary trends in oncology RCTs and compare these findings with earlier eras of RCT design and output.Design, setting, and participantsRetrospective cohort study of systemic therapy RCTs in breast, colorectal, and non-small cell lung cancer published in 7 major journals between 2010 and 2020. This strategy replicates prior work and allows for comparison of trends with RCTs published between 1995 to 2004 and 2005 to 2009.Main outcomes and measuresData on RCT design, funding, results, and reporting were extracted from the published RCT report. Findings from the current period (2010-2020) were compared with data from RCTs published from 1995 to 2004 and 2005 to 2009. Descriptive and bivariate statistics were used to analyze temporal trends.ResultsThe cohort included 298 RCTs (132 [44%] breast, 111 [37%] non-small cell lung cancer, 55 [19%] colorectal cancer). Experimental treatment included molecular inhibitor (171 of 298 [57%]), cytotoxic (83 of 298 [28%]), hormone (15 of 298 [5%]), and immune (24 of 298 [8%]) therapies. Sixty-nine percent (206 of 298) of RCTs were of palliative intent. The most common primary end point is now PFS; this has increased substantially over time (from 0% [0 of 167] to 18% [25 of 137] to 42% [125 of 298]; P

Published
2021

2. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer

Author

Saesen, Robbe, Van Hemelrijck, Mieke, Bogaerts, Jan, Booth, Christopher M., Cornelissen, Jan J., Dekker, Andre, Eisenhauer, Elizabeth A., Freitas, André, Gronchi, Alessandro, Hernán, Miguel A., Hulstaert, Frank, Ost, Piet, Szturz, Petr, Verkooijen, Helena M., Weller, Michael, Wilson, Roger, Lacombe, Denis, and van der Graaf, Winette T.

Published
2023
Full Text
View/download PDF

6. Study Participants, Future Patients, and Outcomes That Matter in Cancer Clinical Trials.

Author

Wilson, Brooke E., Eisenhauer, Elizabeth A., and Booth, Christopher M.

Subjects
*CLINICAL trials, *LITERATURE reviews, *PATIENT participation
Abstract

The article offers information on randomized clinical trials (RCTs) and their impact on defining the efficacy of new cancer treatments, while also examining the debated benefits of trial participation for individual patients. Topics include the existence of a participation effect in cancer RCTs, as explored by Iskander et al, which initially suggested lower mortality risk among trial participants but found this effect diminished when adjusting for confounders and publication bias.

Published
2024
Full Text
View/download PDF

8. Patients' attitudes and preferences toward delayed disease progression in the absence of improved survival.

Author

Brundage, Michael D, Booth, Christopher M, Eisenhauer, Elizabeth A, Galica, Jacqueline, Kankesan, Janarthanan, Karim, Safiya, Koven, Rachel, McDonald, Valerie, Ng, Terry, O'Donnell, Jennifer, Hove, Julia ten, and Robinson, Andrew

Subjects
PATIENTS' attitudes, DISEASE progression, ABDOMINAL tumors, PROGRESSION-free survival, THEMATIC analysis
Abstract

Background Cancer patients' attitudes toward progression-free survival (PFS) gains offered by treatment are not well understood, particularly in the absence of overall survival (OS) gains. The objectives were to describe patients' willingness to accept treatment that offers PFS gains without OS gains, to compare these findings with treatments offering OS gains, and to qualitatively summarize patients' reasons for their preferences. Methods A multicenter, cross-sectional, convergent mixed-methods study design recruited patients who had received at least 3 months of systemic therapy for incurable solid tumors. A treatment trade-off exercise determined the gains in imaging PFS that patients require to prefer additional systemic treatment for a scenario of a newly diagnosed, asymptomatic, incurable abdominal tumor. A qualitative, descriptive, thematic analysis explored factors influencing patients' decisions, and a narrative method integrated the quantitative and qualitative findings. Results In total, 100 patients participated (63% were older than 60 years of age). If additional treatment with added toxicity offered no OS advantage, 17% would prefer it for no PFS benefit; 26% for some PFS benefit (range, 3-9 months), whereas 51% would decline it regardless of PFS benefit. Similarly, 71% preferred additional treatment offering a 6-month OS advantage dependent on described toxicity levels (P  =  .03). A spectrum of reasons for these preferences reflected the complexity of participants' attitudes and values. Conclusions Prolongation of time to progression was not universally valued. Most patients did not prefer treatments that negatively affect quality of life for PFS gains alone. Implications for individual decision making, policy, and trials research are discussed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Author

Ledermann, Jonathan A, Embleton, Andrew C, Raja, Fharat, Perren, Timothy J, Jayson, Gordon C, Rustin, Gordon J S, Kaye, Stan B, Hirte, Hal, Eisenhauer, Elizabeth, Vaughan, Michelle, Friedlander, Michael, González-Martín, Antonio, Stark, Daniel, Clark, Elizabeth, Farrelly, Laura, Swart, Ann Marie, Cook, Adrian, Kaplan, Richard S, and Parmar, Mahesh K B

Published
2016
Full Text
View/download PDF

12. Common Sense Oncology: outcomes that matter

Author

Booth, Christopher M, Sengar, Manju, Goodman, Aaron, Wilson, Brooke, Aggarwal, Ajay, Berry, Scott, Collingridge, David, Denburg, Avram, Eisenhauer, Elizabeth A, Ginsburg, Ophira, Goldstein, Daniel, Gunasekera, Sanjeeva, Hammad, Nazik, Honda, Kazunori, Jackson, Christopher, Karikios, Deme, Knopf, Kevin, Koven, Rachel, Marini, Bernard L, Maskens, Deborah, Moraes, Fabio Y, Mohyuddin, Ghulam Rehman, Poudyal, Bishesh Sharma, Pramesh, C S, Roitberg, Felipe, Rubagumya, Fidel, Schott, Sally, Sirohi, Bhawna, Soto-Perez-de-Celis, Enrique, Sullivan, Richard, Tannock, Ian F, Trapani, Dario, Tregear, Michelle, van der Graaf, Winette, Vanderpuye, Verna, and Gyawali, Bishal

Published
2023
Full Text
View/download PDF

15. Characterizing Variability in Lung Cancer Outcomes and Influence of a Lung Diagnostic Assessment Program in Southeastern Ontario, Canada.

Author

AlGhamdi, Shahad, Kong, Weidong, Brundage, Michael, Eisenhauer, Elizabeth A., Parker, Christopher M., and Digby, Geneviève C.

Subjects
LUNG cancer, CANCER prognosis, LUNGS, OVERALL survival, DATABASES
Abstract

Introduction: Regional variability in lung cancer (LC) outcomes exists across Canada, including in the province of Ontario. The Lung Diagnostic Assessment Program (LDAP) in southeastern (SE) Ontario is a rapid-assessment clinic that expedites the management of patients with suspected LC. We evaluated the association of LDAP management with LC outcomes, including survival, and characterized the variability in LC outcomes across SE Ontario. Methods: We conducted a population-based retrospective cohort study by identifying patients with newly diagnosed LC through the Ontario Cancer Registry (January 2017–December 2019) and linked to the LDAP database to identify LDAP-managed patients. Descriptive data were collected. Using a Cox model approach, we compared 2-year survival for patients managed through LDAP vs. non-LDAP. Results: We identified 1832 patients, 1742 of whom met the inclusion criteria (47% LDAP-managed and 53% non-LDAP). LDAP management was associated with a lower probability of dying at 2 years (HR 0.76 vs. non-LDAP, p < 0.0001). Increasing distance from the LDAP was associated with a lower likelihood of LDAP management (OR 0.78 for every 20 km increase, p < 0.0001). LDAP-managed patients were more likely to receive specialist assessment and undergo treatments. Conclusions: In SE Ontario, initial diagnostic care provided via LDAP was independently associated with improved survival in patients with LC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Author

Rayson, Daniel, Lupichuk, Sasha, Potvin, Kylea, Dent, Susan, Shenkier, Tamara, Dhesy-Thind, Sukhbinder, Ellard, Susan L., Prady, Catherine, Salim, Muhammad, Farmer, Patricia, Allo, Ghasson, Tsao, Ming-Sound, Allan, Alison, Ludkovski, Olga, Bonomi, Maria, Tu, Dongsheng, Hagerman, Linda, Goodwin, Rachel, Eisenhauer, Elizabeth, and Bradbury, Penelope

Published
2016
Full Text
View/download PDF

18. Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life

Author

Brotto, Lori, Brundage, Michael, Hoskins, Paul, Vergote, Ignace, Cervantes, Andres, Casado, Herraez A., Poveda, A., Eisenhauer, Elizabeth, Tu, Dongsheng, and A Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG), the European Organization for Research and Treatment of Cancer—Gynecologic Cancer Group (EORTC-GCG) and the Grupo de Investigación de Cáncer de Ovario (GEICO)

Published
2016
Full Text
View/download PDF

21. Characterizing Regional Variability in Lung Cancer Outcomes across Ontario—A Population-Based Analysis.

Author

Mullin, Monica L., Shellenberger, Jonas, Whitehead, Marlo, Brundage, Michael, Eisenhauer, Elizabeth A., Lougheed, M. Diane, Parker, Christopher M., and Digby, Geneviève C.

Subjects
LUNG cancer, POPULATION, MEDICAL protocols, HEALTH equity
Abstract

Background: Lung cancer (LC) is the leading cause of cancer-related mortality. In Ontario, Canada, there are significant survival differences for patients with newly diagnosed LC across the 14 provincial regions. Methods: A population-based retrospective cohort study using ICES databases from 01/2007–12/2017 identified patients with newly diagnosed LC through the Ontario Cancer Registry and those with LC as the cause of death. Descriptive data included patient, disease, and system characteristics. The primary outcome was 5-year survival by region. Results: 178,202 patient records were identified; 101,263 met inclusion criteria. LC incidence varied by region (5.6–14.6/10,000), as did histologic subtype (adenocarcinoma: 27.3–46.1%). Five-year cancer-specific survival was impacted by age, rurality, pathologic subtype, stage at diagnosis, and income quintile. Timely care was inversely related to survival (fastest quintile: HR 3.22, p < 0.0001). Adjusted 5-year cancer-specific survival varied across regions (24.1%, HR 1.12; 34.0%, HR 0.89, p < 0.001). Conclusions: When adjusting for confounders, differences in survival by health region persisted, suggesting a complex interplay between patient, disease, and system factors. A single approach to improving patient care is likely to be ineffective across different systems. Quality improvement initiatives to improve patient outcomes require different approaches amongst health regions to address local disparities in care. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Author

Stupp, Roger, Hegi, Monika E, Mason, Warren P, van den Bent, Martin J, Taphoorn, Martin JB, Janzer, Robert C, Ludwin, Samuel K, Allgeier, Anouk, Fisher, Barbara, Belanger, Karl, Hau, Peter, Brandes, Alba A, Gijtenbeek, Johanna, Marosi, Christine, Vecht, Charles J, Mokhtari, Karima, Wesseling, Pieter, Villa, Salvador, Eisenhauer, Elizabeth, Gorlia, Thierry, Weller, Michael, Lacombe, Denis, Cairncross, J Gregory, and Mirimanoff, René-Olivier

Published
2009
Full Text
View/download PDF

46. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Author

Stupp, Roger, Brandes, Alba A., Belanger, Karl, Taphoorn, Martin J. B., Fischer, Barbara, Weller, Michael, Bent, Martin J. van den, Mason, Warren P., Marosi, Christine, Lacombe, Denis, Allgeier, Anouk, Gorlia, Thierry, Ludwin, Samuel K., Janzer, Robert C., Curschmann, Jurgen, Bogdahn, Ulrich, Cairncross, J. Gregory, Mirimanoff, Rene O., and Eisenhauer, Elizabeth

Subjects
Temozolomide -- Usage, Temozolomide -- Research, Radiotherapy -- Health aspects, Radiotherapy -- Research, Glioblastoma multiforme -- Diagnosis, Glioblastoma multiforme -- Research
Abstract

The current standard of care for newly diagnosed glioblastoma, the most common primary brain tumor in adults, is surgical resection to the extent feasible, followed by adjuvant radiotherapy. Radiotherapy alone was compared with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy in terms of efficacy and safety.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results